Oct 24, 2019
Soligenix Receives US Patent for Improved Production of Synthetic Hypericin Composition
Oct 03, 2019
Soligenix to Present at the 20th Annual GCFF Investor Conference in Vancouver, British Columbia, Canada
Aug 28, 2019
Soligenix Announces Positive Recommendation by Independent Data Monitoring Committee on its Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer
Aug 15, 2019
Soligenix Announces $150,000 NIH Small Business Innovation Research Award Supporting Evaluation of SGX942 in Pediatric Indications
Aug 13, 2019
Soligenix Announces Recent Accomplishments And Second Quarter 2019 Financial Results
Jul 31, 2019
Soligenix Announces Conference Presentations Demonstrating Formulations of Single and Multivalent Ebola Subunit Vaccines
Jul 29, 2019
Soligenix Receives European Patents for Oral BDP in the Treatment of Acute Radiation Injury of the Gastrointestinal Tract
Jul 08, 2019
Soligenix Announces Appointment of Diane L. Parks to its Board of Directors
Jun 13, 2019
Soligenix to Present RiVax® Program at the 13 Annual CounterACT Network Research Symposium
May 28, 2019
Soligenix Announces $600,000 Subaward Supporting Evaluation of Innate Defense Regulator Platform Technology as a Medical Countermeasure for Bacterial Threat Agents
May 14, 2019
Soligenix Announces Recent Accomplishments And First Quarter 2019 Financial Results
Apr 18, 2019
Soligenix Achieves Significant Enrollment Milestone for its Pivotal Phase 3 Clinical Trial of SGX942 in the Treatment of Oral Mucositis in Head and Neck Cancer
Apr 09, 2019
Soligenix and the European Medicines Agency Pediatric Committee Reach Agreement on the Pediatric Investigation Plan for SGX942
Apr 04, 2019
Soligenix Receives US Patent for Dusquetide Related Analogs
Mar 26, 2019
Soligenix Announces Recent Accomplishments and Year-End 2018 Financial Results
Mar 18, 2019
Soligenix to Present at National Institutes of Health - Commercialization Accelerator Program "FeedForward Session" in Washington, DC
Mar 11, 2019
Soligenix to Present at the Boston Oncology Investor Conference 2019
Feb 11, 2019
Soligenix Receives US Patent Expanding Protection for its Ricin Toxin Vaccine, RiVax®
Feb 07, 2019
Soligenix Announces Publication Demonstrating Thermostabilization of an Ebola Subunit Vaccine Candidate
Jan 23, 2019
Soligenix Receives European Patent for Dusquetide and Related Innate Defense Regulator Analogs